Skip to main content

Month: January 2023

Talenom Plc will publish its Financial Statements Bulletin for 2022 on Tuesday 31 January 2023 at 9:00 EET

Talenom Plc, Press release 17 January 2023 at 10:00 EET Talenom Plc will publish its Financial Statements Bulletin for 2022 on Tuesday 31 January 2023 at 9:00 EET Talenom Plc will publish its Financial Statements Bulletin for 2022 on Tuesday 31 January 2023 at 9:00 EET. The company’s CEO Otto-Pekka Huhtala, CFO Matti Eilonen and CMO Tuomas Iivanainen will present the main points of the review for analysts, investors and media live on a webcast on 31 January 2023 at 10:00 EET. The webcast will be held in English. Participants can ask questions during the webcast via the chat function of the video platform in both Finnish and English. A recording of the webcast will be available after the event on the company website http://investors.talenom.com/en You can watch the webcast online at https://talenom.videosync.fi/financial-statement-2022 The...

Continue reading

Municipality Finance issues EUR 1.5 billion benchmark under its MTN programme

Municipality Finance PlcStock exchange release 17 January 2023 at 10:00am (EET) Municipality Finance issues EUR 1.5 billion benchmark under its MTN programme Municipality Finance Plc issues EUR 1.5 billion benchmark on 18 January 2023. The maturity date of the benchmark is 18 January 2028. The benchmark bears interest at a fixed rate of 2.875 % per annum. The notes are issued under MuniFin’s EUR 45 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the benchmark are available in English on the company’s website at www.munifin.fi/investor-relations. MuniFin has applied for the benchmark to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 18 January 2023. BofA Securities...

Continue reading

Advantest Opens Registration for International VOICE 2023 Developer Conference, May 9-10

Premier User Test Conference to Feature More than 80 Technical Presentations, Partner’s Expo, Keynotes, Workshop Day and More TOKYO, Jan. 17, 2023 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has begun accepting registration from semiconductor test professionals around the world to participate in its VOICE 2023 Developer Conference, held on May 9-10, in Santa Clara, California. Under the theme “Beyond the Technology Horizon,” this year’s conference welcomes the international community of users and strategic partners involved with Advantest’s V93000 and T2000 SoC test platforms, as well as its system-level test solutions, handlers, test cell and cloud solutions. The VOICE 2023 program features extensive opportunities for attendees to learn, including more than 80 presentations...

Continue reading

Standard Lithium Adds Claudia D’orazio and Anca Rusu to the Board, Expanding Project Management, Financial and Human Resources Expertise

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, announces that two experienced energy executives, Claudia D’Orazio and Anca Rusu, have joined its Board as independent directors of the Company, effective immediately. “We are pleased to welcome Claudia and Anca to Standard Lithium’s Board of Directors during such an important stage of growth for the Company,” said Robert Cross, Chairman of the Board. “Both are accomplished senior executives who bring decades of experience in the energy sector. Claudia’s technical and financial acumen and human resources expertise, coupled with Anca’s experience in project development and focus on safety and environmental excellence,...

Continue reading

VEON provides update on voting on Scheme

Amsterdam, Netherlands, 17 January 2023: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON) (“VEON” or, together with its subsidiaries, the “Group”), a global digital operator that provides converged connectivity and online services, and its subsidiary VEON Holdings B.V. (the “Company”) refers to its prior announcements in relating to the Company’s proposed scheme of arrangement (the “Scheme”) in respect of the 5.95% notes due February 2023 and 7.25% notes due April 2023 issued by the Company (together, the “2023 Notes”). The Company has today provided an update on voting on the Scheme. Capitalised terms used but not otherwise defined herein shall have the meaning given to them in the Explanatory Statement, which is available via the Scheme Website at https://deals.is.kroll.com/veon. As set out in the Explanatory Statement, in order to...

Continue reading

Share buybacks in Spar Nord Bank – transactions in week 02

Company announcement no. 03 In company announcement no. 9 2022, Spar Nord announced a share buyback programme of up to DKK 225 million. The share buyback was initiated on 15 June 2022. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 02, the following transactions were made under the share buyback programme.  Number of shares Average purchase price Transaction value (DKK)Accumulated from last announcement 2,315,500     201,215,79209 January 2023  12,000  112.41  1,348,92010 January 2023  12,000  110.50  1,326,00011 January 2023  12,000  111.55  1,338,60012 January 2023  13,000  110.03  1,430,39013 January 2023  13,000  108.18  1,406,340Total...

Continue reading

Karolinska Development’s portfolio company Umecrine Cognition is granted Orphan Drug Designation by the FDA for golexanolone

STOCKHOLM, SWEDEN – January 17, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the company´s most advanced drug candidate golexanolone in Primary Biliary Cholangitis (PBC). The designation will play a vital role in the planned clinical development of golexanolone. The U.S. Food and Drug Administration is granting Orphan Drug Designations to investigational therapies addressing rare medical diseases and conditions that affect fewer than 200.000 people in the United States. Umecrine Cognition is developing golexanolone, a new class of drugs being evaluated in primary biliary cholangitis (PBC) and hepatic encephalopathy (HE). “It is indeed an important and meaningful step...

Continue reading

Vulcan and Stellantis Explore Geothermal Energy to Supply Rüsselsheim Plant

Vulcan and Stellantis Explore Geothermal Energyto Supply Rüsselsheim PlantProject marks Stellantis’ first potential use of geothermal energy to decarbonize and localize its European operations, among renewable energy supply portfolio Stellantis plans to be the industry champion in climate change mitigation, becoming carbon net zero by 2038, with a 50% reduction by 2030 Vulcan and Stellantis will evaluate business models, including selling electricity to public grid in accordance with Germany’s Renewable Energy Act (EEG) Agreement with Stellantis increases Vulcan’s decarbonizing impact on the European electric vehicle industry, complementing the carbon avoidance from its Zero Carbon Lithium™ ProjectAMSTERDAM, January 17, 2023 – Stellantis N.V. and Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL) have signed a binding...

Continue reading

Danone announces an ambitious plan to reduce its methane emissions

Press Release – Paris, January 17th, 2023 Danone announces an ambitious plan to reduce its methane emissionsDanone targets a 30% absolute reduction in methane emissions from fresh milk used in its dairy products, the first food company to align targets with the Global Methane Pledge To accelerate its efforts, Danone launches a new partnership with Environmental Defense FundDanone, a leading food company and one of the world’s largest dairy companies, announces today a global action plan to reduce absolute methane emissions from its fresh milk supply chain by 30% by 20301. Danone expects to remove 1.2 million tons carbon dioxide equivalent of methane emissions by 2030. This ambitious plan builds on the progress Danone has been making in recent years, already reducing its methane emissions by c. 14% between 2018 to 2020. A reduction...

Continue reading

Statkraft and Copenhagen Infrastructure Partners team up to develop 2.2GW of offshore wind in Ireland

(17 January 2023) Statkraft has announced a major deal with Copenhagen Infrastructure Partners’ (CIP) fund Copenhagen Infrastructure IV K/S (CI IV) as part of its plans to develop up to 2.2 gigawatts of offshore wind in Ireland. This landmark partnership will see CIP acquire a 50% stake in Statkraft’s offshore wind portfolio in Ireland. The financial terms of the deal have not been disclosed. The scope of the partnership includes the three phases of the North Irish Sea Array, or NISA, and the Bore Array. The proposed location for NISA is off the coast of counties Dublin, Louth, and Meath, while the site of the Bore Array has been proposed for the Celtic Sea. Developing and building these projects is expected to require an investment of more than €4 billion by Statkraft and CIP by 2030. “The need for energy security and decarbonisation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.